RESUMEN
CONTEXT: Intrauterine infection is thought to be one cause of preterm premature rupture of the membranes (PPROM). Antibiotic therapy has been shown to prolong pregnancy, but the effect on infant morbidity has been inconsistent. OBJECTIVE: To determine if antibiotic treatment during expectant management of PPROM will reduce infant morbidity. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: University hospitals of the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. PATIENTS: A total of 614 of 804 eligible gravidas with PPROM between 24 weeks' and 0 days' and 32 weeks' and 0 days' gestation who were considered candidates for pregnancy prolongation and had not received corticosteroids for fetal maturation or antibiotic treatment within 1 week of randomization. INTERVENTIONS: Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days vs a matching placebo regimen. Group B streptococcus (GBS) carriers were identified and treated. Tocolysis and corticosteroids were prohibited after randomization. MAIN OUTCOME MEASURES: The composite primary outcome included pregnancies complicated by at least one of the following: fetal or infant death, respiratory distress, severe intraventricular hemorrhage, stage 2 or 3 necrotizing enterocolitis, or sepsis within 72 hours of birth. These perinatal morbidities were also evaluated individually and pregnancy prolongation was assessed. RESULTS: In the total study population, the primary outcome (44.1 % vs 52.9%; P=.04), respiratory distress (40.5% vs 48.7%; P=.04), and necrotizing enterocolitis (2.3% vs 5.8%; P=.03) were less frequent with antibiotics. In the GBS-negative cohort, the antibiotic group had less frequent primary outcome (44.5% vs 54.5%; P=.03), respiratory distress (40.8% vs 50.6%; P=.03), overall sepsis (8.4% vs 15.6%; P=.01), pneumonia (2.9% vs 7.0%; P=.04), and other morbidities. Among GBS-negative women, significant pregnancy prolongation was seen with antibiotics (P<.001). CONCLUSIONS: We recommend that women with expectantly managed PPROM remote from term receive antibiotics to reduce infant morbidity.
Asunto(s)
Quimioterapia Combinada/uso terapéutico , Rotura Prematura de Membranas Fetales/tratamiento farmacológico , Enfermedades del Prematuro/epidemiología , Adulto , Amoxicilina/administración & dosificación , Amoxicilina/uso terapéutico , Ampicilina/administración & dosificación , Ampicilina/uso terapéutico , Portador Sano/tratamiento farmacológico , Portador Sano/fisiopatología , Método Doble Ciego , Eritromicina/administración & dosificación , Eritromicina/uso terapéutico , Femenino , Rotura Prematura de Membranas Fetales/microbiología , Humanos , Recién Nacido , Recien Nacido Prematuro , Embarazo , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Complicaciones Infecciosas del Embarazo/fisiopatología , Resultado del Embarazo , Segundo Trimestre del Embarazo , Tercer Trimestre del Embarazo , Modelos de Riesgos Proporcionales , Estadísticas no Paramétricas , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/fisiopatología , Streptococcus agalactiaeRESUMEN
OBJECTIVE: Our goal was to determine the false-negative and false-positive rates of antepartum testing by use of the modified biophysical profile. STUDY DESIGN: From Jan. 1, 1990, through Dec. 31, 1994, antepartum testing results were gathered prospectively and tabulated monthly. For 1 year, 1991, detailed intrapartum and neonatal data were collected from all women admitted and delivered as a result of an abnormal antepartum test result. RESULTS: The false-negative rate of the antepartum testing protocol was 0.8 per 1000 women tested. Sixty percent of those delivered because of an abnormal antepartum test had no evidence of short-term or long-term fetal compromise. False-positive test results led to preterm delivery in 1.5% of those tested before term. CONCLUSION: The false-negative rate of the modified biophysical profile is lower than that of the nonstress test and compares favorably with the false-negative rates of the contraction stress test and the complete biophysical profile. Iatrogenic prematurity resulting from intervention for false positive test results occurred in 1.5% of women tested before 37 weeks.
Asunto(s)
Monitoreo Fetal , Feto/fisiología , Adulto , Fenómenos Biofísicos , Biofisica , Distribución de Chi-Cuadrado , Reacciones Falso Negativas , Reacciones Falso Positivas , Femenino , Frecuencia Cardíaca Fetal , Humanos , Embarazo , Embarazo de Alto Riesgo , Estudios ProspectivosRESUMEN
OBJECTIVE: To determine whether a decreased incidence of nonreactive nonstress tests (NSTs) in antepartum testing was attributable to the addition of fetal movement detection to the standard NST. METHODS: Monitors with standard fetal heart rate recording capabilities were used, as were new monitors producing a Doppler-detected recording of fetal movement (NST-fetal movement). Cross-sectional retrospective analysis of NST results was carried out by chi 2. RESULTS: Comparison of the 10-month period before fetal movement detection to the 10 months including NST-fetal movement monitoring showed a significant decrease in nonreactive NSTs from 5.7% to 3.3% (chi 2 = 61.7, 95% confidence interval [CI] 0.97-0.98). This reduction in nonreactive tests disappeared (3.3% to 5.1%) when the NST-fetal movement-capable monitors were no longer available (chi 2 = 24.2, 95% CI 1.01-1.03). CONCLUSIONS: Nonreactive NSTs decreased by 58% with the introduction of fetal movement monitoring in our antepartum testing center and increased when the NST-fetal movement-capable monitors were removed. A reduced incidence of nonreactive NSTs associated with NST-Doppler-detected fetal movements should effect a savings in both time and resources.
Asunto(s)
Monitoreo Fetal/métodos , Movimiento Fetal/fisiología , Frecuencia Cardíaca Fetal/fisiología , Ultrasonografía Prenatal , Distribución de Chi-Cuadrado , Estudios Transversales , Femenino , Humanos , Embarazo , Estudios RetrospectivosRESUMEN
Management of the post-term pregnancy depends on the certainty of dating, likelihood of successful induction, and risks of expectant management. To estimate the risk of fetal death in an expectantly managed post-term population, we reviewed 8038 consecutive post-term gestations followed expectantly with a twice-weekly nonstress test and amniotic fluid index. There were nine antepartum fetal deaths and no intrapartum fetal deaths, a fetal mortality rate of 1.12 per 1000. Timing of delivery of the post-term gestation balances this risk of loss of a viable fetus with the risks of uncertain dating and failure of induction of labor.
Asunto(s)
Muerte Fetal/epidemiología , Monitoreo Fetal , Posmaduro , Femenino , Edad Gestacional , Humanos , Recién Nacido , EmbarazoRESUMEN
Four patients with hypertensive disorders of pregnancy were treated with intravenous diazoxide. In 2 patients there was profound maternal hypotension. Late deceleration of the fetal heart rate occurred in 3 patients following diazoxide administration. Possible implications of this study are discussed.
Asunto(s)
Diazóxido/uso terapéutico , Hipertensión/tratamiento farmacológico , Complicaciones Cardiovasculares del Embarazo/tratamiento farmacológico , Adulto , Diazóxido/efectos adversos , Femenino , Corazón Fetal/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hiperglucemia/inducido químicamente , Recién Nacido , Proyectos Piloto , EmbarazoRESUMEN
A single 2-mg dose of quinestrol was demonstrated safe and effective for controlling postpartum lactation and for alleviating breast discomfort. A double-blind comparison to Tace 72 mg every 12 hours for 2 days, and to placebo, was made in 134 patients. The single oral dose of quinestrol showed efficacy equal to the 2-day regimen of Tace. Both were superior to placebo.